Yan Leyfman, MD

Thank you for your support

Yan Leyfman: Honored to Join the Advisory Board of CancerNetwork - OncoDaily Yan Leyfman: Honored to Join the Advisory Board of CancerNetwork / cancer, CancerNetwork, OncoDaily, Oncology, ONCOLOGY/CancerNetwork, Yan Leyfman

Honored to Join the Advisory Board of CancerNetwork - Yan Leyfman

@yleyfman.bsky.social

oncodaily.com/career/advis...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerNetwork

I’m energized to help grow this rising research journal, drive forward novel science, and translate the latest breakthroughs into better care for clinicians and patients around the world. 🔬🩺

Excited to contribute, learn, and collaborate. 🌍

I’m deeply honored to join the Advisory Board of ONCOLOGY / CancerNetwork. 🎉 Thank you to Ariana Pelosci & the editorial team for this invitation — I’m grateful for the opportunity to work alongside such an esteemed group of clinical and scientific leaders. 🙏

Thank you for your support

Thank you for your support.

Thank you for your support.

Stories like these remind us that behind every healthcare career lies a deeply personal “why.”

💭 What’s yours?

🎧 Listen to the full interview here: pod.link/1823798473/e...

#chernobyl #physician #medicine #healthcare #humanity

Grateful to the Humanity Rx Podcast for highlighting my story, my passion for oncology & my commitment to advancing patient care & research innovation.

As one of the few remaining survivors of the after-effects of Chernobyl, my own complex medical journey as a child shaped my path toward medicine.

Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - OncoDaily Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL / Bristol Myers Squibb, cancer, FDA,

Yan Leyfman: FDA Accepts Bristol Myers Squibb’s Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL

@yleyfman.bsky.social @bristolmyerssquibb.bsky.social

oncodaily.com/voices/yan-l...

#Cancer #Oncology #OncoDaily #Health #Medicine

#WomenInLymphoma #VoicesInLymphoma #HemeOnc #OncologyMentorship #WomenInMedicine #CareerDevelopment #GlobalOncology #LymphomaLeadership #MentorshipMatters #MedTwitter #AcademicMedicine #LymphomaCare #OncLive #MedNewsWeek @womeninlymphoma.bsky.social @onclive.bsky.social

📲 Register today! globalmeet.webcasts.com/starthere.js...

👩‍⚕️ Dr. Judith Trotman

Director, Clinical Research Unit, Concord Repatriation General Hospital, Sydney, Australia

Whether you're a trainee, early-career physician, or seasoned clinician, this session will offer inspiration and actionable advice.

👩‍⚕️ Dr. Ann LaCasce

Director, Fellowship Program, Dana-Farber/Mass General Brigham

Associate Professor, Harvard Medical School

Join us for a powerful conversation with two world-renowned leaders in hematology-oncology as they share their journeys, challenges, and insights on mentorship, career growth, and shaping the future of lymphoma care.

🎥 MedNews Week x OncLive x Women in Lymphoma Present:

🌟 Voices in Lymphoma: Women Shaping Care 🌟

Career Development & Mentorship in Medicine

🗓️ Tuesday, August 12

⏰ 6:30 PM EST

#MultipleMyeloma #CAR_T #Talquetamab #RRMM #Oncology #Hematology #CellTherapy #RealWorldEvidence #MyelomaResearch #Immunotherapy #GPRC5D #BCMA

Evidence of sustained CAR-T expansion around day 14

💡 Conclusion:

Talquetamab is emerging as a promising bridging option to BCMA CAR-T, particularly for high-risk, trial-ineligible patients who are otherwise vulnerable to disease progression during CAR-T manufacturing.

Toxicity profile: no grade ≥3 CRS, 2% grade 3 ICANS; common but manageable talquetamab-related side effects (oral 70%, skin 38%, nails 17%)

🧠 CAR-T Outcomes Post-Bridging:

88% overall response rate (54% complete response)

Minimal grade ≥3 toxicity post-infusion

🧬 Bridging Outcomes:

71% response rate to talquetamab

119/134 patients proceeded to CAR-T (98 cilta-cel, 21 ide-cel)

Median talquetamab duration: 23 days

Most received 0.8 mg/kg biweekly

👥 Patient Cohort (n=134):

Median age: 65

Median prior therapies: 5

44% with high-risk cytogenetics

41% with extramedullary disease

85% ineligible for CARTITUDE-1/KarMMa trials

📊 Study Overview:

A multi-institutional retrospective analysis (20 centers: 18 US, 2 Germany) evaluated talquetamab, a GPRC5D-targeting bispecific antibody, as bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma (RRMM).

It allowed transition to BCMA CAR-T (cilta-cel or ide-cel) in heavily pretreated, high-risk patients, including many who would not have qualified for clinical trials.

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy Key Points. Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity.Talquetamab enabled transition

🧪 Real-world study supports talquetamab as a viable bridging strategy to BCMA CAR-T in RRMM 🔄

📌 Key Takeaways:

Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.

Thank you

Thank you for your support

#MitochondrialDonation #mtDNA #ReproductiveMedicine #GeneticCounseling #WomensHealth #PrecisionMedicine #MitochondrialDisease #FertilityInnovation

Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease | NEJM Pathogenic variants in mitochondrial DNA (mtDNA) are a common cause of severe, often fatal, inherited metabolic disease. A reproductive care pathway was implemented to provide women carrying pathog...

This marks a major step forward in preventing transmission of mitochondrial disease and offering families new hope through advanced reproductive technologies.

manuscript: www.nejm.org/doi/full/10....

🔹 All infants had no or low mtDNA heteroplasmy

🔹 Minor postnatal issues were manageable and resolved

🔹 Normal developmental progress observed in all children

Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease | NEJM Pathogenic variants in mitochondrial DNA (mtDNA) are a common cause of severe, often fatal, inherited metabolic disease. A reproductive care pathway was implemented to provide women carrying pathog...

🧬✨ Hope Through Mitochondrial Donation

A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births.